Google DeepMind described Co-Scientist, a Gemini-based multi-agent system that generates and tests scientific hypotheses, after a Stanford team used it to surface a drug candidate that blocked 91 percent of a scarring response in lab tests.
DeepMind unveils Co-Scientist, an AI research partner that already helped find a liver-disease drug candidate
Google DeepMind described a system called Co-Scientist, a multi-agent artificial intelligence built on its Gemini models that is designed to work alongside researchers by generating, debating and refining scientific hypotheses. Rather than answering a single question, the system runs several specialized AI agents that propose ideas, critique one another and rank the most promising directions, with the goal of accelerating the slow early stages of discovery. The work was reported in the journal Nature on May 19, 2026.
The most concrete early result came from medicine. A team led by Gary Peltz at Stanford University School of Medicine used Co-Scientist to look for existing, already-approved drugs that might be repurposed to treat liver fibrosis, the scarring that drives chronic liver disease. The system highlighted overlooked candidates, and in laboratory tests one of them blocked 91 percent of a scarring-linked response, a striking result the team published separately in Advanced Science.
“Rather than answering a single question, the system runs several specialized AI agents that propose ideas, critique one another and rank the most promising directions, with the goal of accelerating the slow early stages of discovery.”
The tool has been applied beyond the liver. DeepMind and its collaborators reported uses in antimicrobial-resistance research, plant immunity and the biology of cellular aging, where Omar Abudayyeh's lab said the system cut some analysis from months to days. Partners on the broader effort include researchers at MIT, the University of Cambridge, the University of Edinburgh and Calico Life Sciences, reflecting an attempt to test the approach across very different fields.
The honest framing matters. Co-Scientist proposes hypotheses; it does not prove them, and every lead still demands laboratory work, peer review and, for any drug, years of clinical testing before it could reach patients. Multi-agent systems can also generate plausible-sounding but wrong ideas, so human scientists remain firmly in charge of deciding what to pursue. Used carefully, though, a tool that helps overworked labs spot promising directions they might have missed is a genuinely useful addition to the scientific toolkit, one that aims to amplify human curiosity rather than replace it.
How did this story make you feel?
📎 Cite this article
Good News Good Vibes. (2026, May 19). DeepMind unveils Co-Scientist, an AI research partner that already helped find a liver-disease drug candidate. Retrieved from https://goodnewsgoodvibes.com/en/article/deepmind-co-scientist-multi-agent-ai-accelerate-research-2026
https://goodnewsgoodvibes.com/en/article/deepmind-co-scientist-multi-agent-ai-accelerate-research-2026
Editorial Team
Our editorial team curates and verifies positive news from credible sources worldwide.
Last reviewed: May 19, 2026
Trending
For 30 Years, Oakland Neighbors Have Volunteered to Keep an Urban Creek Pristine
Community · 4 minA Clever Coating Pushes Tandem Solar Cells Toward Higher Efficiency
Science · 5 minThe Iberian Lynx Keeps Climbing: Population Jumps 19% to More Than 2,400
Animals · 5 minFor the First Time Ever, Wind and Solar Out-Generated Gas Worldwide
Environment · 5 minOn Holiday in Nashville, a British Officer Tackled an Attacker and Saved an American Cop
Human Stories · 4 min